The linked FDA records identify Orthocon, Inc. as the applicant on a 510(k) premarket notification for a bone putty and as the addressee of a clearance letter for a related bone paste. The two records sit under different product codes and regulation names, so they describe distinct regulatory identities rather than one filing. The collection snapshot retrieved on November 20, 2026 contains one linked 510(k) record, decided SESE, and no recall records. That count describes the supplied filings only and says nothing about total company sales, total portfolio or safety performance. [1][5][9]

The Permatage XT putty filing

K262769 covers Permatage XT Settable Nonabsorbable Hemostatic Bone Putty, submitted under identifier OS-PER-1001XT. The FDA record lists product code MTJ, classification name Wax, Bone, device class U, review advisory committee OR, and a decision of Substantially Equivalent dated September 3, 2026. The application was received August 4, 2026, carries clearance type Special, was not third-party reviewed, and is accompanied by a summary. The applicant of record is Orthocon, Inc. [1][5][7]

The filing address on the FDA record is 700 Fairfield Ave., Suite 1, Stamford, CT 06902, with Alyssa McDermott listed as contact. That is a correspondence address attached to the submission, not a verified corporate headquarters. The same record carries an openFDA device name of Wax, Bone and an unknown medical specialty description, which limits what can be said about the clinical setting. [1][5]

A separate paste clearance

A March 13, 2026 FDA letter addresses Orthocon, Inc. at the same Stamford address, care of regulatory consultant Howard Schrayer, regarding K253732 for Permatage Flowable, Settable Bone Paste. That letter cites regulation number 21 CFR 882.5300, Methyl Methacrylate For Cranioplasty, regulatory class II and product code GXP. The submission is dated February 9, 2026 and was received February 10, 2026. [9]

The K253732 letter compares the flowable paste with a predicate device and references an earlier Orthocon submission, K241027, for Permatage Settable Bone Putty. The paste and the putty therefore appear as related but separately identified products in the public information. The XT putty record under MTJ is not the same filing as the GXP paste letter, and neither document supplies performance data. [9]

Listing and third-party indexing

An establishment registration and device listing entry shows proprietary name Permatage XT Settable Bone Putty under classification name Methyl Methacrylate For Cranioplasty, product code GXP, device class 2. That listing pairs the XT name with a different product code than the K262769 clearance, which carries MTJ. The public documents do not explain the difference, so the relationship between the two code assignments remains unresolved. [6]

Third-party indexes repeat the K262769 details. FDA.report lists the same applicant, product code, decision and dates, and shows earlier Orthocon entries including HEMASORBPLUS press Resorbable Hemostatic Bone Putty from 2014 and HBP4 Hardening, Resorbable Hemostatic Bone Putty from 2014. RecallHawk reports 19 FDA actions for the company, described as device clearances with no recalls, and states that a 510(k) clearance means the FDA found the device substantially equivalent to a legally marketed device. Those counts originate with that publisher and are not confirmed by the linked FDA records. [5][8]

What the record supports

The documented product identities are the XT putty cleared under K262769 and the flowable paste addressed in the K253732 letter, with the earlier K241027 putty referenced inside that letter. The supplied collection snapshot holds one linked 510(k) record, decided SESE, and no recall sample; the smaller record sample likewise contains that single SESE decision. These are as-of counts of supplied filings, not measures of company output or safety. Ownership, parentage, website, customers and commercial availability are not established by the sources. [1][5][9]